Full Press Release Details
Cancer Patients who Underwent IceCure's ProSense Cryoablation in Japan Reported Significantly Higher Satisfaction than Patients
who Underwent Standard of Care Surgery
Israel, March 10, 2025 - IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"),
developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal,
today announced the publication of an independent study titled "Post-treatment patient satisfaction in early-stage breast cancer:
Comparison of cryoablation versus breast conservation therapy using BREAST-Q" in the peer reviewed journal Gland Surgery.
The study was conducted at the Breast Center, Kameda Medical Center in Kamogawa, Chiba, Japan by the co-authors of the article, Dr. Kizuki
Matsumoto, Dr. Yuko Asano, Dr. Hiroki Matsui, and Dr. Eisuke Fukuma. A leading expert and breast surgeon, Dr. Eisuke Fukuma has performed
over 600 ProSense breast cryoablation procedures, has presented on ProSense and has trained other doctors at medical conferences.
the de-escalation of treatment for breast cancer continues, with breast-conserving therapy ("BCT"), typically defined as
standard of care breast surgery or lumpectomy, representing approximately 60% of all breast cancer cases, as novel nonsurgical options
this study we aimed to evaluate and compare patient satisfaction after BCT and cryoablation. Assessing the patient's health-related
quality of life ("HRQOL") holds significant clinical importance and studies examining long-term satisfaction following cryoablation,
particularly in Asian patients, are limited," stated Dr. Kizuki Matsumoto. "Because of improved survival outcomes, breast
cancer is becoming a chronic disease, making the survivor's quality of life and satisfaction a major focus of treatment. We were
pleased with the outcome of the study and believe the use of cryoablation in breast cancer will be more widespread in the future."
Chief Executive, Eyal Shamir commented, "We are grateful to the team at Kameda Medical Center for initiating this important study
which focuses on women's satisfaction. The data clearly demonstrate that cryoablation resulted in greater quality of life and patient
satisfaction than standard of care surgery in this early-stage breast cancer patient population. We believe these results will support
our distribution partner, Terumo Corporation, in its application for regulatory approval of ProSense for breast cancer in Japan."
The ProSense Cryoablation System is a minimally invasive cryosurgical tool that provides the option to destroy tumors
by freezing them. The system uniquely harnesses the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor
destruction in benign and cancerous lesions, including breast, kidney, lung, and liver.
enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its easy, transportable
design and liquid nitrogen utilization, ProSense opens that door to fast and convenient office-based procedures for breast tumors.
Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors
(benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology
is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The
Company's flagship ProSense system is marketed and sold worldwide for the indications cleared and approved to date including in
the U.S., Europe and China.
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates,"
"intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations
of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements
in this press release when it discusses: the belief that assessing HRQOL holds significant clinical performance; the belief that cryoablation
for treating breast cancer will be more widespread in the future; the belief that the data from the Kameda Medical Center study demonstrate
that cryoablation resulted in greater quality of life and patient satisfaction than standard of care surgery in the early-stage breast
cancer patient population; and the belief that the results from the Kameda Medical Center study will support Terumo Corporation in its
application for regulatory approval of ProSense for breast cancer in Japan. Historical results of scientific research and clinical
and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions.
Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in
these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's
available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory
developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers,
distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property;
the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in
the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual
Report on Form 20-F for the year ended December 31, 2023 filed with the SEC on April 3, 2024, and other documents filed
with or furnished to the SEC which are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update
these statements for revisions or changes after the date of this release, except as required by law.